Literature DB >> 16302007

Hypertension prevention: from nutrients to (fortified) foods to dietary patterns. Focus on fatty acids.

A Grynberg1.   

Abstract

Diet affects significantly the incidence and severity of cardiovascular diseases and fatty acid intake, in its qualitative as well as quantitative aspects, and influences several risk factors including cholesterol (total, LDL and HDL), triglycerides, platelet aggregation and blood pressure, as evidenced in the 2001 WHO report. This review focuses on the qualitative concern of lipid intake, the various classes of fatty acids of the lipid fraction of the diet, saturated, monounsaturated and polyunsaturated, and their effects on blood pressure. Saturated fat have a bad file and several experimental studies in the rat showed a progressive increase in blood pressure in response to a highly saturated diet. Moreover, a highly saturated diet during gestation led to offspring which, when adults, presented a gender-related hypertension. The mechanism of this effect may be related to the polyunsaturated/saturated ratio (p/s). During the past 20 years, trans fatty acids have been suspected of deleterious health effects, but the investigations have shown that these fatty acids display a biological behaviour close to that of saturated fatty acids (SFA). Moreover, epidemiological investigations did not confirm the relationship between trans fatty acids and cardiovascular pathology. Polyunsaturated fatty acids have been shown to exert a positive action on hypertension. This effect could be attributed to the alteration of the p/s, but mainly to the omega3 polyunsaturated fatty acids (PUFAs). The comparison of several animal models led to the conclusion that long-chain omega3 PUFAs (eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)) can prevent the increase in blood pressure and reduce established hypertension, but the efficient dose remains an object of discussion. Moreover, the two long-chain omega3 PUFAs, EPA and DHA, display specific effects, which vary with the aetiology of hypertension, because their mechanism of action is different. DHA acts on both blood pressure and heart function (heart rate and ECG) and interferes with the adrenergic function. Conversely, EPA, which is not incorporated in cardiac phospholipids, has no effect on the heart and its mechanism of action is largely unknown. Although it is accepted by the scientific community that the intake of EPA and DHA needs to be increased, we will have to discover new ways to do it, since marine products are the main source of these fatty acids, and this source is not inexhaustible.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16302007     DOI: 10.1038/sj.jhh.1001957

Source DB:  PubMed          Journal:  J Hum Hypertens        ISSN: 0950-9240            Impact factor:   3.012


  17 in total

1.  Short-term reproducibility of ambulatory blood pressure monitoring in autosomal dominant polycystic kidney disease.

Authors:  Frederic F Rahbari-Oskoui; Dana C Miskulin; Marie C Hogan; Odicie Fielder; Vicente E Torres; James E Bost; Arlene Beth Chapman
Journal:  Blood Press Monit       Date:  2011-04       Impact factor: 1.444

2.  Heart rate is associated with red blood cell fatty acid concentration: the Genetics of Coronary Artery Disease in Alaska Natives (GOCADAN) study.

Authors:  Sven O E Ebbesson; Richard B Devereux; Shelley Cole; Lars O E Ebbesson; Richard R Fabsitz; Karin Haack; William S Harris; Wm James Howard; Sandra Laston; Juan Carlos Lopez-Alvarenga; Jean W MacCluer; Peter M Okin; M Elizabeth Tejero; V Saroja Voruganti; Charlotte R Wenger; Barbara V Howard; Anthony G Comuzzie
Journal:  Am Heart J       Date:  2010-06       Impact factor: 4.749

Review 3.  Omega-3 Polyunsaturated Fatty Acids Intake and Blood Pressure: A Dose-Response Meta-Analysis of Randomized Controlled Trials.

Authors:  Xin Zhang; Jennifer A Ritonja; Na Zhou; Bingshu E Chen; Xinzhi Li
Journal:  J Am Heart Assoc       Date:  2022-06-01       Impact factor: 6.106

4.  Polyunsaturated fatty acids: From diet to binding to ppars and other nuclear receptors.

Authors:  A Bordoni; M Di Nunzio; F Danesi; P L Biagi
Journal:  Genes Nutr       Date:  2006-06       Impact factor: 5.523

5.  Are the Adaptogenic Effects of Omega 3 Fatty Acids Mediated via Inhibition of Proinflammatory Cytokines?

Authors:  Joanne Bradbury; Lyndon Brooks; Stephen P Myers
Journal:  Evid Based Complement Alternat Med       Date:  2011-10-10       Impact factor: 2.629

6.  Fatty acids linked to cardiovascular mortality are associated with risk factors.

Authors:  Sven O E Ebbesson; Venkata S Voruganti; Paul B Higgins; Richard R Fabsitz; Lars O Ebbesson; Sandra Laston; William S Harris; John Kennish; Benjamin D Umans; Hong Wang; Richard B Devereux; Peter M Okin; Neil J Weissman; Jean W MacCluer; Jason G Umans; Barbara V Howard
Journal:  Int J Circumpolar Health       Date:  2015-08-12       Impact factor: 1.228

7.  Relations of plasma polyunsaturated Fatty acids with blood pressures during the 26th and 28th week of gestation in women of Chinese, Malay, and Indian ethnicity.

Authors:  Wai-Yee Lim; Mary Chong; Philip C Calder; Kenneth Kwek; Yap-Seng Chong; Peter D Gluckman; Keith M Godfrey; Seang-Mei Saw; An Pan
Journal:  Medicine (Baltimore)       Date:  2015-03       Impact factor: 1.889

8.  Association between Macronutrients Intake, Visceral Obesity and Blood Pressure in a Sample of Obese Egyptian Women.

Authors:  Nayera E Hassan; Salwa M El Shebini; Nihad H Ahmed; Mohamed Selim Mostafa
Journal:  Open Access Maced J Med Sci       Date:  2015-02-26

9.  Super, red palm and palm oleins improve the blood pressure, heart size, aortic media thickness and lipid profile in spontaneously hypertensive rats.

Authors:  Chee-Meng Boon; Mei-Han Ng; Yuen-May Choo; Shiueh-Lian Mok
Journal:  PLoS One       Date:  2013-02-11       Impact factor: 3.240

Review 10.  The determinants and scope of public health interventions to tackle the global problem of hypertension.

Authors:  Saurabh RamBihariLal Shrivastava; Prateek Saurabh Shrivastava; Jegadeesh Ramasamy
Journal:  Int J Prev Med       Date:  2014-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.